Yosemite Ventures Accelerates Oncology Drug Development

Yosemite, the oncology-focused venture firm established in 2023, is actively deploying capital from its second fund, targeting $350 million. The firm distinguishes itself by not only investing in promising biotech ventures but also by actively creating new companies from early-stage academic research. This dual approach, blending philanthropic grants with external investment, aims to accelerate the development of novel cancer therapies.

Led by Reed Jobs, Yosemite's strategy centers on tackling the 40% of the biotech market dedicated to oncology. The firm's model involves dedicating approximately one-third of its fund to internal company creation, often collaborating with leading academic institutions like Yale, Berkeley, and Stanford. The remaining capital is allocated to investments in companies founded by others. A unique aspect of Yosemite's structure includes a 2.5% allocation of its assets under management to a donor-advised fund, supplemented by $1 million annually from management fees, underscoring a commitment to philanthropic impact alongside financial returns.

The firm highlights significant progress with portfolio companies such as Azalea, which originated from a grant to Jennifer Doudna's lab and has advanced into clinical trials. Another key venture is Quarry, developed in partnership with serial entrepreneur Craig Crews, focusing on induced proximity technology. This innovative therapeutic approach physically brings disease-causing proteins into proximity with the cell's natural degradation machinery, offering a distinct mechanism compared to traditional inhibition methods.

Yosemite's investment thesis is bolstered by a shifting market dynamic. The biotech sector, which experienced a downturn post-pandemic, is now seeing renewed activity. A significant patent cliff looms for numerous blockbuster drugs, coinciding with pharmaceutical companies holding substantial cash reserves. This environment has spurred an increase in M&A, evidenced by high-profile acquisitions like Eli Lilly's $7 billion purchase of Kelonia and strong performance in antibody-drug conjugates. Companies like Revolution Medicines are achieving notable clinical milestones, such as doubling survival rates in pancreatic cancer patients by targeting previously undruggable mutations like KRAS.

Furthermore, Yosemite is navigating the evolving landscape of scientific research funding. While concerns about potential cuts to the National Institutes of Health (NIH) budget have persisted, bipartisan congressional support has largely shielded the agency from drastic reductions. Jobs advocates for increased NIH funding, noting that its real value has stagnated over the past decade due to inflation, impacting the pace of fundamental scientific discovery that fuels biotech innovation.

The firm's ability to pioneer new therapeutic modalities, such as epigenetic gene editing and targeted gene editing delivery – areas that have historically faced significant technical hurdles – positions Yosemite to capture emerging opportunities. By focusing on creating novel treatments and addressing unmet needs in oncology, Yosemite aims to deliver both substantial financial returns and meaningful advancements in patient care.